Loading
Life sciences · Interventional Study
ClinicalTrials.gov · September 25, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Interventional Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07843212). This is a study registration, not published results. Lead sponsor: Mucahide Emine Fidancı Kuas. Recruitment status: RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 80 participants (ESTIMATED). Conditions: Serratus Posterior Superior Intercostal Plane Block (SPSIPB), Breast Cancer, Toll-Like Receptors. Interventions: PROCEDURE: Serratus posterior superior intercostal plane block; PROCEDURE: Sham SPSIP Procedure. Primary outcome measures: Change in serum TLR4 concentration from baseline to 24 hours after surgery , Baseline (preoperative) to 24 hours after surgery. Brief summary: This study will investigate whether the serratus posterior superior intercostal plane (SPSIP) block improves postoperative recovery after breast cancer surgery. Participants will be randomly assigned to one of two groups. One group will receive an ultrasound-guided SPSIP block, while the other group will undergo a similar procedure without active medication (sham procedure). Both groups will receive standard general anesthesia and postoperative pain management. Postoperative pain intensity, need for additional pain medication, nausea and vomiting, length of hospital stay, and persistent pain at 3 months after surgery will be assessed. Blood samples collected before surgery and at predetermined postoperative time points will be used to evaluate the body's inflammatory response to surgery and innate immune system activity. These assessments will include toll-like receptor 4 (TLR4), an immune-system marker, and selected inflammatory markers. The main question of this study is whether the SPSIP block, compared with the sham procedure, reduces the surgery-related inflammatory response and improves postoperative pain outcomes.